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Abstract
Anterior gradient 2 (AGR2) is a dimeric protein disulfide
isomerase family member involved in the regulation of protein
quality control in the endoplasmic reticulum (ER). Mouse AGR2
deletion increases intestinal inflammation and promotes the
development of inflammatory bowel disease (IBD). Although
these biological effects are well established, the underlying
molecular mechanisms of AGR2 function toward inflammation
remain poorly defined. Here, using a protein–protein interaction
screen to identify cellular regulators of AGR2 dimerization, we
unveiled specific enhancers, including TMED2, and inhibitors of
AGR2 dimerization, that control AGR2 functions. We demon-
strate that modulation of AGR2 dimer formation, whether
enhancing or inhibiting the process, yields pro-inflammatory
phenotypes, through either autophagy-dependent processes or
secretion of AGR2, respectively. We also demonstrate that in
IBD and specifically in Crohn’s disease, the levels of AGR2
dimerization modulators are selectively deregulated, and this
correlates with severity of disease. Our study demonstrates that
AGR2 dimers act as sensors of ER homeostasis which are
disrupted upon ER stress and promote the secretion of AGR2
monomers. The latter might represent systemic alarm signals
for pro-inflammatory responses.
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Introduction
The regulation of protein homeostasis (proteostasis) in the endo-
plasmic reticulum (ER) has recently emerged as an important patho-
physiological mechanism involved in the development of different
diseases (Hetz et al, 2015). The capacity of the ER to cope with the
protein misfolding burden is controlled by the kinetics and thermo-
dynamics of folding and misfolding (also called proteostasis bound-
ary), which are themselves linked to the ER proteostasis network
capacity (Powers et al, 2009). The ER ensures proper folding of
newly synthesized proteins through the coordinated action of ER-
resident molecular chaperones, folding catalysts, quality control,
and degradation mechanisms. Anterior gradient 2 (AGR2), a folding
catalyst, binds to nascent protein chains, and it is required for the
maintenance of ER homeostasis (Persson et al, 2005; Higa et al,
2011; Chevet et al, 2013). Loss of AGR2 has been associated with
intestinal inflammation (Park et al, 2009; Zhao et al, 2010), and
several studies have demonstrated that unresolved ER stress leads
to spontaneous intestinal inflammation (Kaser et al, 2013).
Although anterior gradient proteins, including AGR2, were identi-
fied more than a decade ago, their precise biological functions
remain ill-defined. AGR2 was first defined as an ER-resident foldase
(Chevet et al, 2013) and was also shown to exhibit extracellular
activities (Fessart et al, 2016), and all of these functions most likely
depend on protein–protein interactions. Previously, a few AGR2
interacting partners have been identified (Maslon et al, 2010; Yu
et al, 2013) and fewer have been validated as genuine AGR2 binding
partners in the ER. Moreover, biochemical approaches have shown
that AGR2 forms dimers (Ryu et al, 2012; Patel et al, 2013). As
such, this justifies an in-depth study to characterize the protein–
protein interaction-dependent regulatory mechanisms controlling
AGR2 dimerization and functions.
In mammals, AGR2 is generally present in mucus secreting
epithelial cells and is highly expressed in Paneth and goblet intesti-
nal cells, with the highest levels in the ileum and colon (Komiya
et al, 1999; Chang et al, 2008a,b). In goblet cells, AGR2 forms
mixed disulfide bonds with Mucin 2 (MUC2), allowing for its correct
folding and secretion (Park et al, 2009; Zhao et al, 2010). MUC2 is
an essential component of the gastrointestinal mucus covering the
epithelial surface of gastrointestinal tract to confer the first line of
defense against commensal bacteria. Knockout of AGR2 inhibits
MUC2 secretion by intestinal cells, thereby decreasing the amount
of intestinal mucus and leading to a spontaneous granulomatous
ileocolitis, closely resembling human inflammatory bowel disease
(IBD; Zhao et al, 2010). Accordingly, decreased AGR2 expression
and some of AGR2 variants were identified as risk factors in IBD
(Zheng et al, 2006). However, despite the strong link between AGR2
and the etiology of IBD, the molecular mechanism by which AGR2
regulates its activity and contributes to the development of IBD still
remains elusive. To unveil the molecular functions of AGR2 and its
pathophysiological roles, we have developed the ER Mammalian
protein–protein Interaction Trap (ERMIT), which allows us to
specifically detect AGR2 protein–protein interactions in the ER. We
found that upon ER proteostasis alteration AGR2 dimer was
disrupted and a siRNA screen using ERMIT identified TMED2 as a
major regulator of AGR2 dimerization. Moreover, we demonstrated
that variations in TMED2 expression resulted in AGR2 secretion and
pro-inflammatory phenotypes in vitro, in mouse models and in
patients’ samples. Hence, we propose that ER proteostasis-mediated
control of AGR2 dimerization, which might depend on TMED2,
promotes AGR2 release in the extracellular environment thereby
enhancing monocyte recruitment and pro-inflammatory phenotypes.
Results
AGR2 forms stress-regulated homodimer in the
endoplasmic reticulum
Structural studies showed that AGR2 forms dimers through residues
E60 (Fig 1A) and C81 (Ryu et al, 2012; Patel et al, 2013), respec-
tively. Results involving E60 in AGR2 dimerization were confirmed
using molecular dynamics (Fig 1B). The dimeric versus monomeric
equilibrium of AGR2 was also investigated using molecular
▸Figure 1. AGR2 dimerization with ERMIT assay, principles, and validation of the method.The ERMIT assay relies on the signaling properties of IRE1, one of the three ER stress sensors and reports for a dimerization event occurring in the lumen of the ER. The assay
can be applied to heterodimerization or homodimerization events.
A Upper panel: NMR structure of the non-covalent dimer of AGR2 (PDB ID: 2LNS). The dimer domain is highlighted with a yellow circle (residue 54–70 of each
monomer). Monomer A is colored green and monomer B in pink. The figure was generated in Chimera. Lower panel: a close-up illustration of the dimer domain,
showing that the dimer is stabilized through two salt bridges between E60 and K64 of each monomer.
B Molecular modeling showing root-mean-square deviation (RMSD) plot for the MD simulation of the AGR2 WT and E60A mutant. The interaction energies are
defined as the sum of the short-range Coulomb interactions and the short-range Lennard-Jones potential between monomer A and B.
C, D Western blot showing the expression of AGR2 dimers (D) and monomers (M) in HEK293T subjected to DSP-mediated cross-linking and that were previously
transfected with either a control siRNA (siCTL) or a siRNA targeting AGR2 (siAGR2) for 24 h (C) or treated or not with tunicamycin (Tun) prior to cross-linking (D).
Reduced or non-reduced samples were resolved by SDS–PAGE and immunoblotted using anti-AGR2, anti-ERK1, or anti-calnexin (CANX) antibodies (for loading
control).
E Principles of the ERMIT assay. A wild-type IRE1 bait is used to report for dimerization, whereas a kinase catalytic mutant (K599A) is used as a control to prove that
signal observed with the wild-type form is due to IRE1 activation.
F AGR2 dimerization was monitored with ERMIT [wild-type (WT)]. The luminescence signal was abrogated when using the kinase dead (KD) constructs and by the
constructs exhibiting mutations in the dimerization domain [E60A or C81S or double mutant (DM)]. The graph represents average signal normalized on reporter
protein expression  SD [n = 5; **: WT/KD (P = 0.002), E60/WT (P = 0.0034), E60/KD (P = 0.001), C81/KD (P = 0.004), DM/WT (P = 0.0021), and DM/KD
(P = 0.0017), respectively; *: C81/WT (P = 0.0098)]. The Mann–Whitney statistical test was used.
G Cells expressing various bait and prey constructs and the XBP1 splicing reporter or the XBP1 splicing reporter alone were exposed to increasing concentrations of
DTT. The ERMIT signals obtained with both baits were then normalized to that of XBP1s to obtain results independent of the activation of endogenous IRE1 by the
use of chemical ER stressors (n = 4). The graph represents average signal normalized on reporter protein expression SD.
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modeling approaches. Indeed, the reduced dimer stability of the
E60A mutant was verified by performing 200 ns molecular dynam-
ics simulations of wild-type and mutant dimers (Appendix Fig S1A–
F). E60 of each monomer stabilizes the dimer by forming salt
bridges to K64 of the other monomer. The WT system remains
stable throughout the simulation, whereas the E60A mutant form
rapidly dissociates, as identified in increased RMSD, radius of gyra-
tion, and distance measurements, concomitant with loss of interac-
tion energy. These results indicate that AGR2 might exist under
both monomeric and homodimeric forms.
To validate the dimerization of AGR2 in our cellular models, cells
were transfected with a previously validated siRNA against AGR2
(Higa et al, 2011) and its corresponding control siRNA. Cells were
then treated with the chemical cross-linker DSP. Cross-linked
proteins were resolved on either non-reducing (top blot; Fig 1C) or
reducing (middle blot; Fig 1C) conditions and analyzed by Western
blot. Data included in Fig 1C revealed that AGR2 exists predomi-
nantly as homodimers. Since AGR2 is also involved in protein qual-
ity control in the ER (Higa et al, 2011), we evaluated the impact of
ER homeostasis disruption on AGR2 dimerization. DSP-mediated
protein cross-linking of tunicamycin-treated cells revealed that
AGR2 homodimers disappeared upon ER stress induced by tuni-
camycin, whereas total AGR2 expression levels did not change
significantly (Fig 1D).
To further dissect the mechanisms by which AGR2 dimerizes, we
developed the ERMIT assay (Fig 1E). ERMIT is a mammalian two-
hybrid method, adapted from the existing ER-MYTH yeast assay
(Jansen et al, 2012) and based on the functional complementation
of the IRE1 signaling pathway. IRE1 is normally maintained in an
inactive state by its association with the molecular chaperone BiP.
Upon accumulation of misfolded proteins in the ER, initiating ER
stress, IRE1 competes with those proteins for binding to BiP. When
activated, IRE1 cleaves XBP1 mRNA at two consensus sites to initi-
ate an unconventional splicing reaction. This spliced mRNA leads to
the generation of a functional XBP1 transcription factor (Hetz et al,
2015). In the ERMIT assay, the luminal domain of IRE1 was
replaced by different bait proteins (Fig 1E), and independently of ER
stress, bait and prey interactions lead to IRE1 activation and subse-
quent XBP1 splicing. This splicing is monitored by a XBP1 splicing
luciferase reporter system (Hetz et al, 2015).
To determine whether AGR2 dimerizes in the ER, we replaced
the luminal domain of IRE1 with AGR2 wild-type (WT), or two
AGR2 dimerization inactive mutants [E60A, C81A, or the E60A/
C81A double mutant (DM)]. The transmembrane and WT or kinase
dead (KD) cytosolic domains of IRE1 were used as positive controls.
These AGR2-IRE1 chimeric constructs were transfected into
HEK293T cells, and their expression and localization to the ER were
verified by Western blot (Appendix Fig S1G) and immunofluores-
cence microscopy (Appendix Fig S1H). ERMIT signals produced by
HEK293T cells transfected with the different AGR2 baits were then
quantified (Fig 1F). As IRE1 overexpression induces its auto-activa-
tion (Hetz et al, 2015), the ERMIT assay was optimized using low
quantities of the transfected plasmids to ensure that no IRE1 auto-
activation was detectable. In confirmation of the validity of the acti-
vation assay, all the IRE1 KD baits reduced the luminescence signal
by more than 90% (Fig 1F), thus confirming that the signal
observed was not due to the activation of endogenous IRE1. The
AGR2-WT bait produced the highest signal indicating that the
dimerization of AGR2 occurred in the ER. The C81A mutant showed
a 25% decrease in the signal, relative to AGR2-WT, whereas the
E60A or the DM reduced the signal by about 80%. This demon-
strates that AGR2 dimerizes in the ER and that the E60 residue plays
a key role in this in vivo interaction whereas the C81 does not.
Moreover, ER stress induced by DTT treatment showed a dose-
dependent dissociation of AGR2 homodimers as assessed by the
decrease in luminescence observed for all the constructs tested
(Fig 1G). The same result was observed when ER stress was
induced by thapsigargin or tunicamycin (Appendix Fig S1I). An
IC50 was then calculated for each of the ER stressors (Appendix Fig
S1J).
Stress-related AGR2 functions in the ER were also evaluated
using 35S-methionine pulse-chase followed by AGR2 immunoprecip-
itation to investigate the dynamics of AGR2 binding to other part-
ners. Five AGR2 binding partners were visualized using this method
in HeLa cells (bands 1–5, Appendix Fig S2A). Interestingly, the
kinetics of association of these proteins with AGR2 differed between
basal and ER stress conditions. The association of the proteins corre-
sponding to bands 2, 3, and 4 with AGR2 was destabilized upon ER
stress, while that of proteins corresponding to bands 1 and 5 was
stabilized (Appendix Fig S2A). These data led us to propose a model
in which AGR2 exists mainly as a homodimer when protein-folding
demand does not overwhelm the cellular folding capacity but in
case of stress, AGR2 homodimers dissociate to unveil their chaper-
one/quality control properties. Moreover, our data also suggest that
the ratio of monomeric versus dimeric AGR2 might represent a
potent mean to selectively control ER proteostasis.
Identification of AGR2 dimer regulators and functional
characterization of TMED2
To characterize the mechanisms regulating AGR2 dimeric versus
monomeric status, we designed a specific ERMIT-based siRNA
screen and tested the impact of a custom-designed siRNA library
that targets 274 ER-resident proteins (Fig 2A). The counterscreen
used cells transfected only with the XBP1s reporter (Fig 2A). We
identified siRNAs that are positively or negatively modulating AGR2
dimer formation and allowed the identification of proteins that act
as either inhibitors or enhancers of dimerization. A total of 71
proteins representing candidate AGR2 homodimer enhancers (42) or
inhibitors (29) were identified (Fig 2B and Appendix Table S1).
Functional pathway analysis based on Gene Ontology and Reactome
annotations of these candidates revealed an enrichment of AGR2
homodimer enhancers in protein productive folding and ERAD
processes, while AGR2 homodimer inhibitors were significantly
enriched in functions related to calcium homeostasis, ER stress, and
cell death processes (Fig 2C and Appendix Fig S2B–D). Remarkably,
a high network connectivity was observed between dimer enhancers
(green, Fig 2D) or inhibitors (red, Fig 2E), thereby confirming AGR2
functions in productive protein folding when dimeric and managing
misfolded proteins (stress) when monomeric. These data also con-
firm our primary hypothesis and reinforce the importance of AGR2
dimerization control in proper functioning of the ER.
Among the positive regulators of AGR2 dimerization found in the
screen (Fig 2), we identified TMED2, a p24 family member previ-
ously shown to function as a cargo receptor (Barlowe, 1998). More-
over, p24 family members in the yeast Saccharomyces cerevisiae
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were shown to interact with PDI, the family of proteins to which
AGR2 belongs (Appendix Table S2). To further characterize the
functional interaction between TMED2 and AGR2, we first evaluated
whether these 2 proteins could be found in a complex. As such, co-
immunoprecipitations were carried out under basal and ER stress
conditions, either from HEK293T control cells or cells treated with
tunicamycin (Appendix Fig S3A), or from a mouse ligated colonic
loop model before and after treatment with tunicamycin (Fig 3A).
The mouse colon was chosen as both AGR2 and TMED2 are highly
expressed in this tissue. Both in vitro and in vivo, AGR2 was found
in a complex with TMED2 that dissociated upon ER stress (Fig 3A
and Appendix Fig S3A). This observation suggests that under basal
A B
Fold change (effect)
-lo
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p-
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C D E
Stress & apoptosis
Productive folding & ERAD
Figure 2. siRNA screen for identifying regulators of AGR2 dimer formation.
A The first screen was carried out using HEK293T cells transfected with the ERMIT bait/prey, system, the XBP1 splicing reporter, and the siRNA library (n = 5). The
counter screen was carried out using the same experimental setup without the ERMIT bait/prey system (n = 4).
B Volcano plot representing the statistical analysis of the data from the screen, where the y axis represents statistical criteria and the x axis the fold change in
luminescence units.
C Number of genes associated with the indicated processes, as revealed by functional analysis based on Gene Ontology and Reactome terms, (*): Apoptotic signaling
pathway (P = 0.0083), ER-associated degradation (P = 0.0076), and lipid biosynthetic process (P = 0.0059), respectively; (**): ER stress (P = 0.0044), Protein folding
(P = 0.003), Calcium homeostasis (P = 0.0022), N-glycosylation (P = 0.0018), respectively.
D, E Enrichment of AGR2 homodimer enhancers in functions associated with ER homeostasis (green) and of AGR2 homodimer inhibitors in functions associated with ER
homeostasis imbalance (red).
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and stress conditions AGR2 is present in different functional
complexes, a result supported by our siRNA and proteomic screens
(Higa et al, 2011), where AGR2 mainly contributed to import into
the ER, export to the Golgi apparatus or to ERAD (Appendix Fig
S2D). The possible interaction of AGR2 monomer and dimer with
TMED2 was explored using extensive protein–protein docking
(Fig 3B and Appendix Fig S3B–E). The identified interaction orienta-
tions between TMED2 and AGR2 monomer are for the most part
unstable and will block the possibility of AGR2 dimer formation
(Appendix Fig S3B). Docking between TMED2 and AGR2 dimer, on
the other hand, rendered several conformers in which TMED2
simultaneously interacts with both AGR2 monomers in the N-term-
inal/dimer interface regions (Fig 3B), and where perfect comple-
mentarity between structures and electrostatic surfaces of the two
are noted (Appendix Fig S3C–E). We next examined the mecha-
nisms underlying TMED2 regulation of AGR2 homodimerization.
TMED2 overexpression led to enhanced AGR2 homodimer forma-
tion as evaluated using DSP-mediated cross-linking (Fig 3C). To
further characterize the functional role of the interaction between
TMED2 and AGR2, we sought to generate a mutant AGR2 unable to
interact with TMED2, thereby not directly affecting TMED2
functions. To this end, a molecular modeling approach was under-
taken to identify amino acid residues involved in the TMED2-AGR2
interaction and revealed that K66 and Y111 might play key roles
(Fig 3D). As such, K66 and Y111 were mutated to alanine residues
(referred to as AGR2 AA hereafter) and the interaction between
AGR2 and TMED2 was evaluated using co-immunoprecipitation. As
expected, whereas AGR2wt and TMED2 co-immunoprecipitated, the
interaction between TMED2 and AGR2 AA was impaired (Fig 3E).
Of note, the expression levels of AGR2 AA were lower than those of
AGR2 WT, suggesting that TMED2 might also regulate the
expression of this protein independently of their interaction. We
next monitored the impact of TMED2 expression alteration on AGR2
level. Interestingly, overexpression of TMED2 led to reduced
expression of AGR2 (Fig 3F), and reduced ERMIT signals, correla-
tive to the loss of expression (Fig 3G). In contrast, the silencing of
TMED2 led to enhanced expression of AGR2 (Fig 3H), but decreased
ERMIT signals, indicative of effective dimerization inhibition
(Fig 3I).
AGR2 dimerization ability does not affect its chaperone functions
but alters its localization
To explore the functional relevance of AGR2 dimerization, we tested
how AGR2 regulates cargo secretion. As such the previously
described interactions of AGR2 with the two plasma-membrane GPI-
anchored proteins CD59 and LYPD3, that were reported in proteo-
mics studies, were confirmed using ERMIT with the monomeric
AGR2 E60A used as bait and either CD59 or LYPD3 used as preys,
OS9 was used as a negative control (Fig 4A). Furthermore, we
monitored the AGR2 contribution to the ER quality control and
protein secretion using CD59 WT and mutant form, CD59 C94S. The
latter due to its misfolding is no longer efficiently exported to the
cell membrane and accumulates in the ER lumen (Fig 4B) even
though the expression levels are similar (Fig 4C). We also found
that both AGR2 WT and AA interacted with GFP-CD59 WT or C94S
(Fig 4D and E). Interestingly, the modification of AGR2 and TMED2
expression levels impacted on CD59 degradation and trafficking
(Fig 4F and G). Indeed, although AGR2 silencing led to reduced
expression of intracellular CD59 WT (25%) and CD59 C94S (50%),
it did not impact further on the expression of both proteins at the
cell surface, thereby suggesting a role of intracellular AGR2 in qual-
ity control in the ER (Fig 4F and G). TMED2 silencing led to reduced
expression of intracellular CD59 (either WT or C94S), and a similar
effect was observed for cell surface expression (Fig 4F and G, and
Appendix Fig S4A and B). These data indicated that the interplay
between AGR2 and TMED2 exerts a selective regulation on protein
folding and trafficking and contributes to protein quality control in
the ER. To test the functionality of AGR2 AA, rescue experiments
were carried out and showed that overexpression of either AGR2
WT or AGR2 AA restored the expression of GFP-CD59 (WT or C94S)
total and at the cell surface (Fig 4H and I), thereby indicating that
AGR2 AA conserved its ability to participate to ER folding and qual-
ity control mechanisms.
Further, we sought to investigate the impact of AGR2 on the
secretion of cargo proteins under normal and ER stress conditions.
Given that AGR2 peptide binding sites are present on alpha-1-anti-
trypsin (A1AT; Appendix Fig S4C), we tested if AGR2 impacts on
the secretion of this cargo. We examined the effect of silencing of
◀ Figure 3. Validation of AGR2-TMED2 interaction and its impact on AGR2 dimerization./TMED2 functional relationships with AGR2.A Co-immunoprecipitation of AGR2 with TMED2 under basal and tunicamycin induced ER stress in intestinal epithelial cells treated in situ. *indicates Immunoglobulin
heavy and light chains.
B Structural association of TMED2 and AGR2. The six TMED2 orientations (pink, dark pink, purple, blue, yellow, and green) best positioned to stabilize the AGR2 dimer
(colored tan with N-termini and dimer interface alpha helix in red).
C Changes in AGR2 dimer and monomer ratio in TMED2 overexpressing cells. DSP-stabilized AGR2 was analyzed under non-reducing (top blot) or reducing conditions
(bottom blot). D = dimeric, M = monomeric AGR2.
D Specific interactions between residues in AGR2 dimer (tan) and best oriented TMED2 structure (green). Glu51, Arg74, and Arg97 of TMED2 form ionic interactions with
Lys66, Glu59, and Asp97 of AGR2. His28 of TMED2 interacts with Tyr111 of AGR2 through p-p-interactions.
E Co-immunoprecipitation of AGR2 wild-type (WT, left panel) or AGR2 AA mutant (right panel) with TMED2 in HEK293T cells. Immunoprecipitation was performed with
mouse anti-Flag antibody to pull-down the ectopic protein tag.
F Western blot analysis (left panel) and quantification (right panel) of AGR2 intracellular expression upon TMED2 overexpression. Data are representative of four
independent experiments. Tubulin (TUB) was used as a loading control. The graph represents average signal normalized on reporter protein expression SD. The
Mann–Whitney statistical test was used.
G HEK293T cells were transfected with control (ev) or TMED2 plasmid and then used in the ERMIT assay with AGR2 WT as described in Fig 1E (n = 3). The graph
represents average signal normalized on reporter protein expression SD.
H Western blot analysis (left panel) and quantification (right panel) of AGR2 intracellular expression in total cell lysate (TCL) upon TMED2 silencing. Data are
representative of 4 independent experiments. Tubulin (TUB) was used as a loading control. The graph represents average signal normalized on reporter protein
expression SD. The Mann–Whitney statistical test was used.
I HEK293T cells were silencing for TMED2 and then used in the ERMIT assay with AGR2 WT as described in Fig 1E (n = 3). The graph represents average signal
normalized on reporter protein expression SD.
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Figure 4. AGR2 status alteration impacts on client protein biogenesis.
A The ERMIT-based validation of the complex formation between AGR2 and LYPD3 or CD59, but not OS9. The monomeric AGR2 E60A was used as bait, while LYPD3,
CD59, and OS9 were used as prays (n = 6). The graph represents average signal normalized on reporter protein expression SD. For statistical analyses, the Mann–
Whitney test was used.
B, C Expression and subcellular localization of CD59-GFP WT and C94S.
D, E Co-immunoprecipitation of CD59-GFP WT or CD59 C94S mutant with AGR2 WT (D) or AGR2 AA mutant (E) in HEK293T cells.
F–I FACS analysis of CD59 WT (F and G) or CD59 C94S (H and I) total (F and H) and membrane (G and I) expression in HEK293T cells silenced for AGR2 (siAGR2) and
TMED2 (siTMED2) when compared to control (siGL2) cells (F and H) or silenced for TMED2 (siTMED2) and overexpressing AGR2 WT or AGR2 AA mutant (G and I).
Data are representative of three to four independent experiments. Membranous CD59 expression was detected with anti-GFP APC. ns: non-statistically significant;
for (F) (*): P = 0.0385, (***): P = 0.0003 (left panel) and P = 0.0002 (right panel), respectively; for (G) (*): P = 0.0334, (**) P = 0.0036, and (***) P = 0.0003; for (H) (*):
P = 0.0171 and (**): P = 0.0084; and for (I) (**) P = 0.0086 (left panel) and P = 0.0076 (right panel), respectively. The graph represents average GFP signal SD. For
statistical analyses, the Mann–Whitney test was used.
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AGR2 on secretion of A1AT by immunoblot under basal and stress
conditions (Appendix Fig S4D and E). Under basal conditions, AGR2
was not involved in the secretion of A1AT as the silencing of AGR2
did not affect the kinetics of A1AT secretion. However, upon ER
stress the retention of A1AT in the ER was decreased in the absence
of AGR2. This suggests that AGR2 might also be involved in sensing
ER homeostasis. Lastly, as shown in Appendix Fig S4F, the presence
of AGR2 stabilized the expression of MUC2 in HT29 cells, further
confirming a crucial role for AGR2 in ER proteostasis. In addition,
treatment of HT29 cells with the PTTIYY peptide (AGR2 binding;
Clarke et al, 2011) rescued MUC2 expression upon ER stress
(Appendix Fig S4G), suggesting the importance of the AGR2/MUC2
interaction in MUC2 quality control.
Since we observed an impact of TMED2 expression changes on
iAGR2 expression levels, we sought to investigate the underlying
molecular mechanisms involved in this phenomenon. First, the
effects of overexpression of TMED2, which seemed to decrease the
levels of intracellular AGR2 (iAGR2; Fig 3), were not reversed by
ERAD pharmacological inhibitors (Appendix Fig S5A). However, we
found that this occurred through an alternative degradation mecha-
nism involving autophagy (Fig 5A and B) and was reversed by
chloroquine treatments (Fig 5C and D). This pointed toward an
lysosomal/autophagy-dependent degradation of AGR2 induced by
TMED2 overexpression. However, when we tested the presence of
AGR2 in the extracellular milieu, we detected an anti-AGR2
immuno-reactive band with an unexpected electrophoretic mobility
(~37 kDa; Appendix Fig S5E). This indicated that cells overexpress-
ing TMED2 might present aberrant secretion features. This was con-
firmed by analyzing the insoluble material released by TMED2
overexpressing cells using cryo-electron microscopy that presented
a very heterogenous profile of extracellular vesicles (and CD63
staining) compared to control cells (Fig 5F). Collectively, these data
show that overexpression of TMED2 leads to the abnormal secretory
features including the release of aberrant AGR2 entities. TMED2
silencing, on the other hand, resulted in the increase of the intracel-
lular fraction of AGR2 (iAGR2, Fig 3) and promoted elevated AGR2
secretion in the medium (eAGR2; Fig 5G and H). Finally, we tested
how constitutively monomeric (E60A) or dimeric (D45) AGR2 form
behaved regarding secretion. Our results indicate that AGR2 E60A
was secreted more efficiently than AGR2 WT and in the contrary,
AGR2 D45 was retained inside the cell (Fig 5I). Importantly, TMED2
overexpression or silencing did not impact further the secretion of
AGR2 AA (Appendix Fig S5B and C) thereby demonstrating the
dependency of AGR2/TMED2 interactions for AGR2 secretion.
Together, these results indicate that alteration of AGR2 dimeric
versus monomeric status impacts on AGR2 release in the extracellu-
lar milieu (either as a part of an altered secretory material or as a
monomer). At last, TMED2 overexpression led to the release of
AGR2 in a way that suggested the involvement of the endo-lyso-
somal system. This was also observed upon treatment of the cells
with Brefeldin A that prompted a bafilomycin A1-sensitive release of
AGR2 (Appendix Fig S5D). The alternative release of AGR2 might
therefore occur through a non-conventional secretion mechanism.
Pathophysiological implication of AGR2 dimerization control
Since AGR2 was involved in hypersensitivity of intestinal epithelium
to inflammation (Zhao et al, 2010) and since TMED2 was found to
regulate AGR2 dimeric status, we postulated that mice exhibiting
altered TMED2 expression should also display an intestinal pheno-
type. To test this hypothesis, we evaluated the expression of AGR2
and MUC2 in the intestine of mice expressing lower levels of TMED2
(heterozygous deficient; Hou et al, 2017). Interestingly, typical signs
of chronic intestinal inflammation were observed in TMED2 hypo-
morph mice such as loss of mucosecretion, inflammatory cell infil-
trate, and hyperproliferation of mucosa in both the proximal colon
and ileum (Fig 6A). These observations were associated with appar-
ent lymphocytosis (Fig 6A). Furthermore, TMED2 hypomorph mice
exhibited lower global expression level of both AGR2 and MUC2
than WT mice (Fig 6B and C), thereby partly phenocopying the
results observed in AGR2 deficient mice. As we recently showed
that eAGR2 could exert signaling properties on cells by inducing
▸Figure 5. Cellular mechanisms of AGR2 secretion.A Formation of GFP-LC3 autophagic puncta in TMED2 overexpressing HEK239T cells as monitored using confocal microscopy (right panel). DAPI was used for nuclear
staining visualization. Percentage of GFP-LC3 puncta in control (CTL) and TMED2 overexpressing HEK293T cells as quantified from three independent experiments by
counting 240 GFP-LC3 positive cells for each condition (left panel). (**): P = 0.0032. The graph represents average western blot normalized signal SD. For statistical
analyses, the Mann–Whitney test was used.
B Western blot detection (left panel) and quantification (right panel) of LC3 level in control and TMED2 overexpressing HEK293T cells treated or not with 50 lM
chloroquine for 2 h. Actin (ACT) served as a loading control. (*): P = 0.0498. The graph represents average western blot normalized signal SD. For statistical analyses,
the Mann–Whitney test was used. n = 4.
C Western blot analysis of AGR2 expression in control and TMED2 overexpressing HEK293T cells upon autophagy inhibition with 20 and 10 lM chloroquine treatment.
Actin (ACT) served as a loading control.
D HEK293T cells were transfected with control (ev) or TMED2 plasmid and then used in the ERMIT assay with AGR2 WT as described in Fig 1E in the presence of
gradual amounts of chloroquine. The graph represents average signal SD. For statistical analyses, the Mann–Whitney test was used, n = 4.
E Western blot analysis of secreted AGR2 upon TMED2 overexpression. eAGR2, extracellular AGR2; iAGE2, intracellular AGR2.
F Representative pictures of extracellular vesicles (EVs) heterogeneity purified from conditioned media of HEK293T cells transfected with control (ev) or TMED2 plasmid
and analyzed by cryo-electron microscopy. Right upper panel: Western blot analysis of CD63 in total medium (left) and in the purified extracellular vesicles fraction
purified from media conditioned by control and TMED2 overexpressing cells (middle) and Western blot analysis of AGR2 levels (right) in extracellular vesicles enriched
from culture media conditioned by control and TMED2 overexpressing cells.
G Western blot analysis of secreted AGR2 upon TMED2 silencing eAGR2, extracellular AGR2; iAGE2, intracellular AGR2.
H Quantification of extracellular AGR2 level (eAGR2) in cells silenced for TMED2 (siTMED2), compared to control (siGL2). Data are representative of three independent
experiments and are presented as extracellular-to-intracellular AGR2 ratio. (**): P = 0.0029. The graph represents average western blot normalized signal SD. For
statistical analyses, the Mann–Whitney test was used.
I Secretion of AGR2 wild-type (wt), E60A, and Δ45 mutant as determined by Western blot. eAGR2, extracellular AGR2; iAGE2, intracellular AGR2.
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EMT programs (Fessart et al, 2016), and since in our cellular
models TMED2 silencing led to enhanced released of eAGR2, we
reasoned that eAGR2 might also play a role in the chemoattraction
of pro-inflammatory cells. To determine the direct involvement of
eAGR2 in chemoattraction, PBMCs purified from three independent
healthy donors were exposed either to media conditioned by cells
overexpressing AGR2 WT, E60A, D45, or AA. Chemoattraction of
monocytes from PBMCs was observed only when AGR2 was found
in the extracellular milieu, namely when conditioned media from
cells transfected with AGR2 WT, E60A, or AA was used (Fig 6D).
Similar results were obtained when using media from cells overex-
pressing AGR2 WT or AA and simultaneously overexpressing
TMED2 (Fig 6E and F), media from cells silenced for TMED2
(Fig 6G) or even recombinant human AGR2 (Fig 6H). Remarkably,
AGR2 blocking antibodies were able in all cases to impede mono-
cytes migration (Fig 6E, F and I). These experiments revealed that
in all cases, eAGR2 was able to selectively promote monocyte attrac-
tion, thereby linking eAGR2 to pro-inflammatory phenotypes and
unraveling the extracellular gain-of-function of AGR2 as a pro-
inflammatory chemokine. Collectively, our results link the interac-
tion between TMED2 and AGR2 and by extend the monomeric
versus dimeric status of AGR2 to pro-inflammatory phenotypes in
the intestine. To test the relevance of these results in human IBD,
we first evaluated the expression levels of the pathophysiological
relevance of AGR2 dimer regulators in colonic biopsies from
patients with IBD. Fifty-two of the 71 candidates presented in
Appendix Table S1 were first tested in non-inflamed colonic biopsies
from healthy controls, patients with ulcerative colitis (UC) and
patients with Crohn’s disease (CD), the two main classes of IBDs
(Appendix Table S3). Messenger RNA expression levels of 12 out of
52 genes were found to be significantly different in CD while only 3
showed significant differences in UC (Appendix Fig S6). The expres-
sion differences in AGR2 modulators were exacerbated in colonic
CD patients (CC; Fig 7A). To corroborate these findings, a validation
cohort consisting of healthy controls and patients with ileo-colonic
CD was used to evaluate mRNA expression levels of the 52 genes of
interest. Fourteen genes, including the 12 genes previously
identified, were significantly different in patients with CD, support-
ing the initial findings (Appendix Fig S6B). This allowed for the dif-
ferentiation of CD patients from healthy controls (Fig 7B).
Moreover, a functional enrichment analysis revealed that 6 genes
whose silencing disrupted AGR2 dimer formation were either up-
regulated or down-regulated in CD (namely TMED2, RPN1, KTN1,
LMAN1, AMFR, AKAP6) and that 4 genes whose silencing promoted
AGR2 dimerization were systematically down-regulated in CD
(namely P4HTM, SYVN3, CES3, SCAP). TMED2 mRNA (Fig 7C) and
protein (Fig 7D) expression was increased in CD, mainly in normal
intestinal epithelial cells. TMED2 overexpression was detected in
patients with active (A) CD and correlated with high recruitment of
CD163 positive macrophages in the colonic mucosa (Fig 6E and F).
Remarkably, patients with quiescent (Q) CD exhibited a moderate
loss of AGR2 global staining which likely correlated with its proba-
ble secretion (Fig 7E and F). These data indicate that regulation of
AGR2 dimerization is associated with pro-inflammatory responses
and enrichment of macrophages in the colonic mucosa that could be
observed in CD (Fig 7G). Dissecting the diversity and the local
distribution of functional macrophages in patients with active or
quiescent CD will further define clinical relevance of AGR2.
Discussion
The results presented in this study show that in the ER, AGR2 exists
under monomeric or dimeric configurations and modulation of
AGR2 dimeric versus monomeric status might represent a novel ER
proteostasis sensor mechanism in intestinal epithelial cells. More-
over, we identify a mechanism of regulation of AGR2 dimerization
through an interaction with the protein TMED2. Furthermore, our
data link the perturbation of AGR2 dimerization to inflammatory
bowel disease in human in part through the unexpected intervention
of AGR2 in the recruitment of inflammatory cells. Collectively, our
results document a molecular link between ER proteostasis control
and a pro-inflammatory systemic stress response which when
abnormal turns out as a disease state in the colon.
◀ Figure 6. Alteration of TMED2 expression and relationships with eAGR2-mediated monocytes attraction.A Representative histological H&E staining of sections of the proximal colon and ileum of WT and TMED2 hypomorph mice.
B Immunohistological analysis of AGR2 and MUC2 expression in the proximal colon of WT and TMED2 hypomorph mice.
C Semi-quantitative analysis of AGR2 and MUC2 expression in the proximal colon of WT (blank bars) and TMED2 hypomorph mice (black bars) (n = 6). The graph
represents average IHC signal SD. For statistical analyses, the Mann–Whitney test was used.
D Freshly isolated PBMCs were placed in Boyden chambers toward media conditioned by cells overexpressing AGR2 WT, E60A, Δ45, or AGR2 AA mutants and
incubated for 24 h. Migrating cells were then characterized and quantified by flow cytometry using FCS/SSC parameters or CD14 monocyte marker. (**):
P = 0.0016. The graph represents average IHC signal SD. For statistical analyses, the Mann–Whitney test was used.
E, F Freshly isolated PBMCs were placed in Boyden chambers toward media conditioned by cells overexpressing TMED2 and either AGR2 WT (E) or AGR2 AA mutant (F)
and incubated for 24 h. Migrating cells were then characterized and quantified as indicated in Fig 6D. For (E) (*): P = 0.0461 (AGR2WT/TMED2) and 0.018
(AGR2WT/TMED2 + blocking Ab) respectively; (**): P = 0.0053 and (***): P = 0.0048; for (F) (***): P = 0.0007. The graph represents average IHC signal SD. For
statistical analyses, the Mann–Whitney test was used.
G Freshly isolated PBMCs were placed in Boyden chambers toward media conditioned by cells silenced for TMED2 and incubated for 24 h. Migrating cells were then
characterized and quantified as indicated in Fig 6D. (*): P = 0.0149. The graph represents average IHC signal SD. For statistical analyses, the Mann–Whitney test
was used.
H Freshly isolated PBMCs were placed in Boyden chambers toward decreased doses of recombinant AGR2 and incubated for 24 h. CCL2 cytokine was used as positive
control for monocyte migration. ns: non-statistically significant, (*): P = 0.0171, (**): P = 0.0084, (***): P = 0.0003. The graph represents average IHC signal SD. For
statistical analyses, the Mann–Whitney test was used.
I Impact of AGR2 blocking antibodies on AGR2-mediated monocytes migration was tested using Boyden chambers as described above. The concentrations of
recombinant human AGR2 were of 200 ng/ml, and decreasing amounts of antibodies were used from 20 lg to 1 lg. The non-relevant antibody (Isotype) was used
at the maximal dose of 20 lg. Data are representative of three independent experiments. ns: non-statistically significant, (*): P = 0.0165 (Ab = 20 lg/ml), 0.0223
(Ab = 10 lg/ml) and 0.0493 (Ab = 5 lg/ml), respectively. The graph represents average IHC signal SD. For statistical analyses, the Mann–Whitney test was used.
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We first reasoned that since an excess of AGR2 dimers or AGR2
monomers yields a pro-inflammatory response, a systemic adaptive
reaction, the relative concentrations of each form might be linked to
proper function of the early secretory pathway. In this context,
dysregulation of the relative equilibrium of AGR2 dimers and mono-
mers could be a sign of ER proteostasis imbalance. In the context of
IBD, protein homeostasis within the early secretory pathway and its
adaptation to the perturbation through the UPR have been shown to
play instrumental roles in disease onset (Grootjans et al, 2016). In
the present work, we identified AGR2 as a critical player in such
adaptive mechanism and we further demonstrated that under basal
conditions AGR2 mainly interacts with Golgi export components to
ensure proper protein folding, while during ER stress it forms func-
tional complexes with ERAD machinery to clear the misfolded
proteins from the ER. Moreover, this study provides the identifi-
cation of AGR2 status, monomer versus dimer balance, as an early
event possibly able to define the extent and some characteristics of
intestinal inflammation. This is particularly appealing for IBD,
which is characterized by the chronic inflammation and ulceration
of the gastrointestinal tract due to an overactive immune digestive
system. Our data suggest that perturbation of AGR2 dimerization,
due to variable expression levels of its client proteins, can lead to
IBD development. This could actually be relevant at several levels
through the release of extracellular AGR2 which might as previously
found in other models induce Epithelial-to-Mesenchymal Transition
markers13 to promote fibrosis which is a hallmark of Crohn’s
disease and in the mean-time to promote the recruitment of macro-
phages to the site of damage to precondition the tissue for uncon-
trolled inflammation.
Interestingly, our results also establish that the interaction
between AGR2 and TMED2 plays a key role in AGR2 dimerization
control by stabilizing the dimer. The alteration of TMED2 expres-
sion in mice, resulting from the heterozygous expression of a
mutant form of the protein that is not properly synthesized (Hou
et al, 2017), resulted in alteration of colon homeostasis and
inflammation. Moreover, overexpression of TMED2 was detected in
active CD and may also be associated with inflammation through
autophagy-dependent AGR2 release in the extracellular milieu (Park
et al, 2009; Zhao et al, 2010). A similar mechanism could be applied
to other AGR2 expressing cells, such as pancreatic, biliary, or lung
epithelia. Findings from this study might be further applicable to
cancer biology, since proteostasis imbalance has emerged as a major
cancer hallmark, capable of driving tumor aggressiveness (Chevet
et al, 2015). In light of our findings, control of AGR2 dimerization
may well be a relevant factor in cancer development. High AGR2
expression, as well as its secretion into body fluids, was reported in
many cancer types and associated with pro-tumorigenic phenotype
and poor patient outcome (Chevet et al, 2013; Brychtova et al,
2015; Obacz et al, 2015). However, questions remain as to what is
the predominant form of AGR2 in cancer cells, how is the formation
of AGR2 dimer versus monomer precisely regulated, and what are
the biological/functional consequences of AGR2 dimerization?
These issues warrant deeper investigation. Collectively, our data
provide the first evidence of the existence of ER sensors, such as
AGR2, that contribute to the regulation of proteostasis boundaries in
this compartment, and whose alteration leads to pro-inflammatory
responses.
Materials and Methods
Materials
Tunicamycin (used at 2 lg/ml or otherwise indicated) was from
Calbiochem (Guyancourt, France), thapsigargin (used at 500 nM or
otherwise indicated) was from Calbiochem, Azetidine-2-carboxylic
acid (used at 5 mM or otherwise indicated), and DTT (used at
0.5 mM or otherwise indicated) was from Sigma (St. Louis, MO,
USA). The siRNA library was from RNAi (http://rnai.co.jp/lsci/
products.html). DSP was from Thermo Fisher—Pierce (Villebon-sur-
Yvette, France).
Plasmid constructs
Constructs used in this report were derived from the pcDNA5/FRT/
TO (Invitrogen) plasmid. The segment encoding the transmembrane
and cytosolic domains of IRE1 was cloned in pcDNA5/FRT/TO plas-
mid by standard PCR and restriction-based cloning procedures. All
used primers are listed in Appendix Table S4. Baits and preys
present in the hORFeome v8.1 were directly transferred in the
pcDNA5/FRT/TO/IRE1 using the GatewayTM cloning technology
(Life Technologies). The mutant constructions were obtained by
◀ Figure 7. Expression levels of AGR2, TMED2, and CD163 in biopsies from healthy controls and patients with IBD.A Selective enrichment of AGR2 modulators in colonic Crohn’s disease (CD). Percentage of tested genes with altered expression in colonic biopsies from patients with
ulcerative colitis (UC, n = 8) and colonic CD (CC, n = 15) and in ileal biopsies from patients with ileo-colonic CD (IC, n = 9). t-test was used.
B Hierarchical clustering of the AGR2 modulator genes significantly deregulated in non-inflamed colonic mucosa from patients with Crohn’s Disease (CD) versus healthy
controls (C) (dChip software t-test). Gene expression (blue: fold decrease; red: fold increase).
C TMED2 mRNA expression in healthy controls (CT), colonic Crohn’s disease (CC), and ulcerative colitis (UC). ANOVA was used.
D Representative immunohistological analysis of TMED2 in non-inflamed colonic biopsies from healthy controls and patients with active CD. Scale bars: 100 lm.
E Representative immunohistological analysis of CD163 (scavenger receptor present in macrophages), AGR2, and TMED2 in non-inflamed colonic biopsies from healthy
controls and patients with active or quiescent CD.
F Semi-quantitative analysis of CD163, AGR2, and TMED2 immunostaining in colonic mucosa from healthy controls (C) and patients with quiescent (Q) or active (A) CD.
Three random sections from each patient of the four groups were scored. Final IHC scores (A × B range to 0–9) combine the percentage of positively labeled cells. A:
% of IHC positive labeled cells—0 (0%), 1 (< 30%), 2 (30–60%), 3 (> 60%), and the intensity of the reaction product. B: 0 (no reaction), 1 (weak), 2 (mild), 3 (strong) in
most of the examined fields. All values are mean  SEM. n = 12, ANOVA was used as a statistical test.
G Schematic representation of the role of AGR2 dimer alteration in intestinal epithelial cells under basal conditions or in Crohn’s disease. In normal cells, the ratio of
dimeric versus monomeric AGR2 defines proteostasis boundaries in the ER, and those are altered in diseased conditions through the alteration of the expression of
AGR2 dimer regulators, thereby leading to pro-inflammatory signals comprising the release of AGR2 in the extracellular milieu and to the induction of uncontrolled
autophagy and the subsequent alteration of protein secretion.
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PCR mutagenesis with the QuickChange II Site-Directed Mutagene-
sis Kit (Agilent Technologies) using the different primers presented
in Appendix Table S4. The XBP1 splicing reporter was described
previously (Samali et al, 2010). The hTMED2 expression plasmid
was obtained from Sino Biological (HG13834-CF). The GFP-LC3
plasmid was a kind gift from Dr P. Codogno (Paris, France). AGR2
cDNA (WT, E60A, D45, and AA) were obtained from Genewiz
(Sigma-Aldrich) and were cloned in pcDNA3.1 plasmids.
SiRNA screening
The screen was performed using a custom-made siRNA library
targeting 274 ER-resident proteins. Five thousand HEK293T cells
were seeded in black 96-well plates. One day later, the cells were
transfected with 200 pg of the AGR2/WT bait, 1.5 pmol of siRNA,
and 3 ng of the XBP1 luciferase reporter using the calcium phos-
phate precipitation procedure. In parallel, a counterscreen was
performed by transfecting the siRNAs and the XBP1 luciferase
reporter in the absence of the AGR2 WT bait. Two days after trans-
fection, the luciferase activity was measured by chemiluminescence
in an EnVision Multilabel Plate Reader (PerkinElmer, Waltham, MA,
USA). The raw values were log2 transformed and were normalized
to the average signal of the plate. The average negative signal of the
plate was subtracted, separately for each replicate, and a quantile
normalization was performed. T-test and Kruskal–Wallis statistical
analyses were performed to select the list of significant candidates.
Patients and sample analyses
The experiments conformed to the principles set out in the WMA
Declaration of Helsinki and the Department of Health and Human
Services Belmont Report. Human ascending colon and ileal biopsies
were obtained from the IBD Gastroenterology Unit, Beaujon Hospi-
tal. The protocol was in agreement with the local Ethics Committee
(CPP-Ile de France IV No. 2009/17), and written informed consent
was obtained from all the patients before inclusion. The clinical
characteristics of IBD patients are shown in Appendix Table S3.
Thirty-two healthy controls, eight patients with UC, and 40 patients
with CD were selected (consecutively between 2012 and 2015) and
included in this study. All patients were diagnosed based on classi-
cal clinical features as well as radiological, endoscopic, and histolog-
ical findings. All biopsies were taken from the non-inflamed area of
the right colon or the terminal ileum and analyzed by an expert GI
pathologist. Unaffected areas were defined as mucosal regions with-
out any macroscopic/endoscopic and histological signs of inflamma-
tion. To preserve tissue transcriptional profiles, biopsy specimens
were kept at 80°C until RNA extraction.
Immunohistochemistry
Paraffin-embedded sections of colon were deparaffinized in xylene,
rehydrated, incubated in 3% hydrogen peroxide for endogenous
peroxidase removal, and heated for 10 min in sub-boiling 10 mM
citrate buffer (pH 6.0) for antigen retrieval. Then, sections were
processed using the ImmPRESS reagent kit (Vector Laboratories).
Primary antibodies against CD163 (AbCam, ab87099), TMED2
(Santa Cruz Biotechnology, sc-376459), and AGR2 (Novus Biologi-
cals, NBP1-05936) were used.
Cell culture
HEK293T cells were cultured in a 5% CO2 humidified atmosphere at
37°C and grown in Dulbecco’s modified Eagle’s medium (Invitrogen)
with 10% fetal calf serum (Cambrex Corp.). HeLa, HC116, Caco, and
HT-29 cells were grown in DMEM, 4 g/l glucose, and 10% FBS.
Western blot analysis
Expression of the ERMIT baits and preys was detected using the M2
mouse monoclonal antibody against the FLAG-tag. AGR2 was
detected with H0010551-M03 mouse monoclonal antibody
(Abnova), or with 12275-1-AP rabbit polyclonal antibody (Protein-
tech), TMED2 with sc-376459, C-8 mouse monoclonal antibody
(Santa Cruz Biotechnology), LC3 with D11 XP rabbit monoclonal
antibody (Cell Signaling), CD59 with anti-GFP antibody (Santa Cruz,
Tebu-Bio), and CD63 with EXOAB-CD63A-1 rabbit polyclonal anti-
body (System Biosciences). Expression of actin was detected using
the A2066 rabbit monoclonal antibody (Sigma, St Louis, MO, USA),
tubulin using mouse monoclonal antibody (Sigma) and that of with
mouse anti-p97 antibody (BD Transduction Laboratories). All
primary antibodies were diluted 1:1,000 in PBS 0.1% Tween. Fluo-
rescent goat anti-mouse and anti-rabbit antibodies (LI-COR IRDye
800 CW and 600 CW) at the dilution of 1:2,000 for detection with
the Odyssey imager (LI-COR) or HRP-conjugated secondary antibod-
ies at the dilution of 1:7,000 in PBS 0.1% Tween for chemilumines-
cence imaging.
Chemical cross-linking
HEK293T cells were cultured as described above. Cells were
washed with ice-cold PBS, and cross-linking was performed by
incubating with 1 mM DSP (final concentration) for 20 min on ice.
DSP was then quenched with 50 mM Tris–HCl pH 7.5, 150 mM
NaCl for an additional 20 min on ice. After extensive washing with
ice-cold PBS, cells were lysed using RIPA buffer and analyzed by
Western blotting.
Secretory protein productive folding and secretion analysis
Cells were pulse-labeled with 100 lCi/60 mm dish of EXPRE35S
Protein Labelling Mix (PerkinElmer) for 30 min. Labeled cells were
washed twice with ice-cold PBS and chased in complete medium
(DMEM containing 10% FBS) for 0–4 h. Pulse-labeling and chase
were also carried out in the presence and absence of 5 mM Azeti-
dine-2-carboxylic acid (Azc). Pulse-labeled cells were washed twice
with PBS and incubated in lysis buffer (30 mM Tris–HCl pH 7.5,
150 mM NaCl and 1% Triton X-100) for 30 min on ice and centri-
fuged at 10,000 g for 20 min at 4°C. After pre-clearing using protein
G Sepharose (GE Healthcare Bio-Sciences), lysates were incubated
overnight with anti-AGR2 antibody (1:500) at 4°C. The beads were
then added to the immune complexes and precipitated for 40 min at
4°C with gentle rotation and washed five times with lysis buffer.
Immunoprecipitates were eluted with Laemmli sample buffer
containing 50 mM DTT for 10 min at 70°C. The proteins were
analyzed by both X-ray fluorography and immunoblotting and
detected using LumiGLO chemiluminescent substrate system (Kirke-
gaard & Perry Laboratories).
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Autophagy analysis
This was done according to Klionsky et al (2016). Briefly, HEK293T
cells were transfected with 1 lg C-FLAG tagged expression plasmid
coding for TMED2 using Lipofectamine 2000 reagent (Thermo
Fisher Scientific) according to the manufacturers’ protocol. Twenty-
four hours later, cells were transfected with 1 lg expression plasmid
coding for GFP-LC3 as described above. Cells were then washed
twice with ice-cold PBS and fixed with 4% paraformaldehyde (PFA)
for 20 min at room temperature. GFP-positive cells were visualized
using confocal microscopy (Leica SP8). For autophagy inhibition,
HEK293T cells were co-transfected with 1 lg expression plasmids
coding for AGR2 and TMED2 using Lipofectamine 2000 reagent
following the manufacturers’ protocol. Twenty-four hours post-
transfection, chloroquine was added to the cells at a final concentra-
tion of 20 and 10 lM and incubated for 24 h. Subsequently, cells
were analyzed for AGR2 protein expression by Western blotting
with anti-AGR2 antibody. For LC3 protein detection by Western
blot, HEK293T cells were transfected with 1 lg expression plasmids
coding for TMED2 as described above. Forty-eight hours post-trans-
fections, cells were treated with 50 lM chloroquine for 2 h.
Monocytes chemoattraction assay
Peripheral blood mononuclear cells (PBMCs) were isolated from
healthy donors. PBMCs were washed in RPMI 1% FCS (Life Tech-
nologies), placed in Boyden chambers 3 lm (5 × 105 cells/chamber
in RPMI 1% FCS; Millipore, France) that were placed in RPMI
containing increased concentrations of recombinant AGR2 (Ray-
biotech, Tebu-Bio, Le Perray en Yvelines, France) or conditioned
medium from cells overexpressing AGR2 WT, E60A, Δ45, AA
mutants or/and TMED2 and silenced or not for TMED2; and then
incubated at 37°C for 24 h. The migrated PBMCs (under the Boyden
chambers) were collected, washed in PBS, and cells were stained for
monocytes, T, B, and NK cell markers (anti-CD14, -CD3, -CD19, and
-CD56, respectively) and analyzed by flow cytometry using a FACS-
Canto II flow cytometer (BD Biosciences, Le Pont de Claix, France)
or an ACEA Novocyte flow cytometer (Ozyme, France). Data were
then analyzed using FACSDiva (BD Biosciences) or NovoExpress
(Ozyme). The relative number of migrated cells was estimated by
flow cytometry by counting the absolute number of cells.
Animal experiments: ligated-colonic loops assays
Bred in-house 2-month-old male C57BL/6 mice weighing 22–25 g
were used. All experiments were approved by and conducted in
accordance with the ethical guidelines of the Local Animal Experi-
mentation Committee (Xavier Bichat Medical School) and were in
complete compliance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals. Efforts were made to
minimize any pain or discomfort, and the minimum number of
animals was used. Mice were anesthetized with ketamine/xylazine
(100 mg/kg/10 mg/kg) and kept warm with a 37°C warming pad
during the assay. Colons were flushed with warm PBS to eliminate
stool before surgical ligation. Two contiguous ligated colonic loops
per animal (2 cm in length each) were made between the cecum
and the rectum with black-braided nylon, leaving the mesenteric
blood vessels intact. One hundred microliters of TM solution (1 mg/
ml) or vehicle were injected into the lower and upper ligated colonic
loops, respectively, to avoid potential TM solution efflux in the
control loop. After incubation for 3 h, the mice were euthanized
and the ligated loops were excised from the colon, rinsed with ice-
cold PBS, and stored at 80°C before protein extraction. TMED2
mutant mice—For TMED2 mutant mice, all procedures and experi-
ments were performed according to the guidelines of the Canadian
Council on Animal Care and approved by the Animal Care Commit-
tee of the Montreal Children’s Hospital. The 99J (TMED2 mutant)
mouse line was generated on a C57/BL6J genetic background and
maintained on a mixed C3H genetic background (C3HeB/FeJ and
C3HeB/FeV) as previously described (Hou et al, 2017). Six-month-
old male TMED2 mutants (n = 6) and their wild-type littermate
(n = 6) were analyzed.
Statistical analyses
Graphs and statistical analyses were done using GraphPad Prism 5.0
software (La Jolla, California, USA). When experiment contained
two unmatched groups of values, the nonparametric Mann–Whitney
test was used for the comparison of means. When experiment
contained three groups of values or more, regular one-way analysis
of variance (ANOVA) was used for the comparison of multiple
means. For each experiment, the ANOVA P value is as indicated in
brackets. The ANOVA test was followed by a Bonferroni’s multiple-
comparison post-test, and selected pairs of data were compared.
The Bonferroni P-value is indicated at the bottom of each figure
legend. The nonparametric Spearman test was used to compare
quantitative values of expression. Means were considered signifi-
cantly different if the P < 0.05. Significant variations were repre-
sented by asterisks above the corresponding bar when comparing
the test with the control condition or above the line when compar-
ing the two indicated conditions.
Functional pathway analysis
The functional analysis and the ranking of genes according to their
pivotal role in the underlying molecular network were performed
using the BioInfoMiner web application (https://bioinfominer.com,
Lhomond et al, 2018). The application performs enrichment analy-
sis using the Hypergeometric test to assess the over-representation
of Gene Ontology terms annotated to the initial genes of interest.
For the correction of P-values, the application avoids multiple test-
ing correction methods (Bonferroni, FDR) that tend to promote
enrichments with low biological content (i.e., enrichments corre-
sponding to very specific terms, which are annotated by very few
genes in the background distribution). Instead, it employs a
nonparametric, resampling-based, empirical alternative to multiple
testing corrections, which provides a corrected measure for the
statistical significance of the enrichments based on their frequencies
of observation. Hence, the algorithm prioritizes terms with less
frequent enrichments, which tend to represent broader, more
systemic functions, represented by larger groups of genes (Chatzi-
ioannou & Moulos, 2011; Pilalis & Chatziioannou, 2013; Pilalis et al,
2015). The ranking of genes is performed by a graph-theoretical
method, which corrects the annotation bias of the Gene Ontology
hierarchical network and ranks the related genes according to their
regulatory impact in the corrected semantic network (Moutselos
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et al, 2011; Koutsandreas et al, 2016). The highly ranked genes are
associated with many distinct, cross-talking systemic processes.
Molecular dynamic simulation of AGR2 WT and E60A mutant
The E60A mutant (glutamate to alanine) was obtained through in
silico mutation in Yasara (Krieger & Vriend, 2014). The MD simula-
tions of the AGR2 WT and E60A mutant were performed utilizing
the Gromacs 2016.1 package (Hess et al, 2008) and the Amber ff03
force field (Wang et al, 2000; Duan et al, 2003). For each run, the
protein was solvated in a cubic box with TIP3P water molecules and
a buffer distance of 10 A˚ to the walls. The system was neutralized
by addition of two Na+-ions, and then energy minimized by steep-
est decent until the force was < 1,000 kJ/mol/nm, with a maximum
number of steps of 5,000 to relax bad contacts. By employing peri-
odic boundary conditions, the system was subjected to a position
restraint equilibration run, composed of 500 ps in the NVT ensem-
ble followed by 500 ps in the NPT ensemble to relax the water and
ions around the protein at constant temperature (300 K) and pres-
sure (1 bar). The leap-frog algorithm with a time step of 2 fs was
used for integration of Newton’s second law of motion. Constraints
on all bonds were applied using the LINCS (Hess et al, 1997) algo-
rithm (LINC-iter = 1 and LINC-order = 4). The temperature was
controlled by the Nose–Hoover thermostat (Hoover, 1985) with a
coupling constant of 0.1 ps, and the Parrinello–Rahman barostat
(Parrinello & Rahman, 1981) coupling algorithm was applied to
maintain a constant pressure with a coupling time of 2.0 ps and a
compressibility of 4.5 × 105/bar. Electrostatic interactions were
treated with the Particle Mesh Ewald (PME; Darden et al, 1993;
Essmann, 1995) summation method (Fourier spacing = 16 A˚ and
PME-order = 4), with a short-range electrostatic cut-off of 10 A˚. The
short-range cut-off for van-der-Waals interactions was also set to
10 A˚. The neighbor list for non-bonded interactions was updated
every 10th step through the Verlet cut-off scheme. Following the
equilibration run, a 200 ns unrestraint production run in the NPT
ensemble was performed, utilizing the same settings described
above. All MD simulations were run on the supercomputer cluster
Beskow, provided by the supercomputing center PDC at KTH, Stock-
holm. All analyses of the provided trajectories were performed with
the Gromacs software, and the provided data were plotted, using
Gnuplot (Williams & Kelley, 2015).
Modeling of AGR2/TMED2 interactions
The structure of the Golgi dynamics (GOLD) domain of human
TMED2 (PDB ID: 5AZW; Nagae et al, 2016) and the NMR structure
of the non-covalent dimer of AGR2 (PDB ID: 2LNS; Patel et al,
2013) were downloaded from the Brookhaven protein databank
(Berman et al, 2000) followed by protein preparation in YASARA
(Krieger & Vriend, 2014). Protein–protein docking was performed
by using the web-server PatchDock (Duhovny et al, 2002; Schneid-
man-Duhovny et al, 2005). The AGR2 dimer or AGR2 monomer was
defined as the receptor, and TMED2 was defined as the ligand. In
each docking run, the top 500 decoys were subjected for refinement
and rescoring in the web-server FireDock (Andrusier et al, 2007;
Mashiach et al, 2008) retaining the top 10 scored decoys from each
run. Analysis of interaction energies revealed that the AGR2 dimer
provided significantly stronger interactions with TMED2 than the
monomer. Visual inspection of the monomer and dimer AGR2
complexes with TMED2 and complementarity of their respective
electrostatic surfaces were used to identify most likely interaction
structures. Molecular images and electrostatic surfaces were gener-
ated using Chimera (Pettersen et al, 2004).
Cryo-electron microscopy
Vitrification of purified exosomes was performed using an automatic
plunge freezer (EM GP, Leica) under controlled humidity and
temperature (Dubochet & McDowall, 1981). The samples were
deposited to glow-discharged electron microscope grids followed by
blotting and vitrification by rapid freezing into and were observed
using a 200 kV electron microscope (Tecnai G2 T20 Sphera, FEI)
equipped with a 4k × 4k CCD camera (model USC 4000, Gatan).
Micrographs were acquired under low electron doses using the
camera in binning mode 1 and at a nominal magnifications of
29,000×. Measurements were performed using the measuring tools
available in Fiji (Schindelin et al, 2012).
Expanded View for this article is available online.
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The paper explained
Problem
The molecular mechanisms underlying inflammatory bowel diseases
remain currently not completely understood, and therapeutic options
are scarce.
Results
Herein, we have identified that a normally endoplasmic reticulum
resident protein, member of the protein disulfide isomerase family,
AGR2, exhibits tightly regulated secretion mechanisms that are
perturbed in Crohn’s disease. We demonstrate that the extracellular
release of AGR2 leads to the chemoattraction of monocytes, thereby
suggesting extracellular AGR2’s pro-inflammatory functions, that can
be blocked using specific antibodies.
Impact
As a consequence, this discovery could represent an appealing thera-
peutic approach to attenuate the inflammatory burden in Crohn’s
disease.
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